- Home
- RGP vs ZNTL Comparison
RGP vs ZNTL Comparison
Compare RGP & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGP | ZNTL |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.3M | 118.3M |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RGP | ZNTL |
|---|---|---|
| Price | $5.15 | $1.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $6.00 | $5.87 |
| AVG Volume (30 Days) | 359.2K | ★ 494.2K |
| Earning Date | 01-02-2026 | 11-10-2025 |
| Dividend Yield | ★ 5.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $534,625,000.00 | $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.13 | $1.01 |
| 52 Week High | $9.96 | $3.53 |
Technical Indicators
Market Signals| Indicator | RGP | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 62.78 | 49.62 |
| Support Level | $4.77 | $1.34 |
| Resistance Level | $4.89 | $1.48 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 80.28 | 55.88 |
Price Performance
Historical ComparisonAbout RGP Resources Connection Inc.
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.